Interferon regulatory factor-7 modulates experimental autoimmune encephalomyelitis in mice

Journal of Neuroinflammation

Volumn 8, Issue , 2011, Pages

  Salem, Mohammad ^a   Mony, Jyothi T ^a   Løbner, Morten ^a   Khorooshi, Reza ^a   Owens, Trevor ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Central nervous system; Chemokines; Cytokines; Eae; Inflammation; Irf7; Type i ifn

Indexed keywords

CD11B ANTIGEN; CD3 ANTIGEN; CD3 EPSILON ANTIGEN; CD45 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 17; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BETA INTERFERON; CHEMOKINE; CYTOKINE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CCL2 GENE; CD3 EPSILON GENE; CD3 GENE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CXCL10 GENE; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GAMMA INTERFERON GENE; GENE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTOR 7 GENE; INTERLEUKIN 17 GENE; INTERLEUKIN 1BETA GENE; KNOCKOUT MOUSE; LEUKOCYTE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN DEFECT; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; SPINAL CORD; TH1 CELL; TH17 CELL; UPREGULATION; ANIMAL; C57BL MOUSE; CENTRAL NERVOUS SYSTEM; GENETICS; IMMUNOLOGY; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; CHEMOKINES; CYTOKINES; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INTERFERON REGULATORY FACTOR-7; INTERFERON-BETA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; SPINAL CORD;

EID: 84155176729     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-8-181     Document Type: Article

References (50)

1. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996, 85:299-302.
2. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann Neurol 2009, 65:239-248.
3. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
4. Panitch HS. Early treatment trials with interferon beta in multiple sclerosis. Mult Scler 1995, 1(Suppl 1):S17-21.
5. Giovannoni G, Miller DH. Multiple sclerosis and its treatment. J R Coll Physicians Lond 1999, 33:315-322.
6. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007, 282:20059-20063.
7. Ousman SS, Wang J, Campbell IL. Differential regulation of interferon regulatory factor (IRF)-7 and IRF-9 gene expression in the central nervous system during viral infection. J Virol 2005, 79:7514-7527.
8. Khorooshi R, Owens T. Injury-Induced Type I IFN Signaling Regulates Inflammatory Responses in the Central Nervous System. J Immunol 2010,
9. Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways. Cell Res 2006, 16:141-147.
10. Honda K, Yanai H, Takaoka A, Taniguchi T. Regulation of the type I IFN induction: a current view. Int Immunol 2005, 17:1367-1378.
11. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434:772-777.
12. Benveniste EN, Qin H. Type I interferons as anti-inflammatory mediators. Sci STKE 2007, 2007:pe70.
13. Prinz M, Schmidt H, Mildner A, Knobeloch KP, Hanisch UK, Raasch J, Merkler D, Detje C, Gutcher I, Mages J, Lang R, Martin R, Gold R, Becher B, Bruck W, Kalinke U. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008, 28:675-686.
14. Teige I, Treschow A, Teige A, Mattsson R, Navikas V, Leanderson T, Holmdahl R, Issazadeh-Navikas S. IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J Immunol 2003, 170:4776-4784.
15. Galligan CL, Pennell LM, Murooka TT, Baig E, Majchrzak-Kita B, Rahbar R, Fish EN. Interferon-beta is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitis. Mult Scler 2010, 16:1458-1473.
16. Delhaye S, Paul S, Blakqori G, Minet M, Weber F, Staeheli P, Michiels T. Neurons produce type I interferon during viral encephalitis. Proc Natl Acad Sci USA 2006, 103:7835-7840.
17. Jelinsky SA, Miyashiro JS, Saraf KA, Tunkey C, Reddy P, Newcombe J, Oestreicher JL, Brown E, Trepicchio WL, Leonard JP, Marusic S. Exploiting genotypic differences to identify genes important for EAE development. J Neurol Sci 2005, 239:81-93.
18. Toft-Hansen H, Fuchtbauer L, Owens T. Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease. Glia 2011, 59:166-176.
19. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005, 17:1-14.
20. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008, 118:1680-1690.
21. Prinz M, Garbe F, Schmidt H, Mildner A, Gutcher I, Wolter K, Piesche M, Schroers R, Weiss E, Kirschning CJ, Rochford CD, Bruck W, Becher B. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 2006, 116:456-464.
22. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006, 25:349-360.
23. Brod SA, Scott M, Burns DK, Phillips JT. Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons. J Interferon Cytokine Res 1995, 15:115-122.
24. Kozovska ME, Hong J, Zang YC, Li S, Rivera VM, Killian JM, Zhang JZ. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 1999, 53:1692-1697.
25. Ruuls SR, de Labie MC, Weber KS, Botman CA, Groenestein RJ, Dijkstra CD, Olsson T, van der Meide PH. The length of treatment determines whether IFN-beta prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats. J Immunol 1996, 157:5721-5731.
26. van der Meide PH, de Labie MC, Ruuls SR, Groenestein RJ, Botman CA, Olsson T, Dijkstra CD. Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. J Neuroimmunol 1998, 84:14-23.
27. Babcock AA, Kuziel WA, Rivest S, Owens T. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci 2003, 23:7922-7930.
28. Khorooshi R, Babcock AA, Owens T. NF-kappaB-driven STAT2 and CCL2 expression in astrocytes in response to brain injury. J Immunol 2008, 181:7284-7291.
29. Aravalli RN, Peterson PK, Lokensgard JR. Toll-like receptors in defense and damage of the central nervous system. J Neuroimmune Pharmacol 2007, 2:297-312.
30. Lande R, Giacomini E, Grassi T, Remoli ME, Iona E, Miettinen M, Julkunen I, Coccia EM. IFN-alpha beta released by Mycobacterium tuberculosis-infected human dendritic cells induces the expression of CXCL10: selective recruitment of NK and activated T cells. J Immunol 2003, 170:1174-1182.
31. Zhai Y, Qiao B, Gao F, Shen X, Vardanian A, Busuttil RW, Kupiec-Weglinski JW. Type I, but not type II, interferon is critical in liver injury induced after ischemia and reperfusion. Hepatology 2008, 47:199-206.
32. Jin S, Kawanokuchi J, Mizuno T, Wang J, Sonobe Y, Takeuchi H, Suzumura A. Interferon-beta is neuroprotective against the toxicity induced by activated microglia. Brain Res 2007, 1179:140-146.
33. Muller M, Carter SL, Hofer MJ, Manders P, Getts DR, Getts MT, Dreykluft A, Lu B, Gerard C, King NJ, Campbell IL. CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J Immunol 2007, 179:2774-2786.
34. Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 2001, 193:713-726.
35. Christensen JE, de Lemos C, Moos T, Christensen JP, Thomsen AR. CXCL10 is the key ligand for CXCR3 on CD8+ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. J Immunol 2006, 176:4235-4243.
36. Floris S, Ruuls SR, Wierinckx A, van der Pol SM, Dopp E, van der Meide PH, Dijkstra CD, De Vries HE. Interferon-beta directly influences monocyte infiltration into the central nervous system. J Neuroimmunol 2002, 127:69-79.
37. Stuve O, Chabot S, Jung SS, Williams G, Yong VW. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. J Neuroimmunol 1997, 80:38-46.
38. Liuzzi GM, Latronico T, Fasano A, Carlone G, Riccio P. Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult Scler 2004, 10:290-297.
39. Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest 2007, 117:1119-1127.
40. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007, 13:139-145.
41. Haak S, Croxford AL, Kreymborg K, Heppner FL, Pouly S, Becher B, Waisman A. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest 2009, 119:61-69.
42. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006, 177:566-573.
43. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008, 14:337-342.
44. Sweeney CM, Lonergan R, Basdeo SA, Kinsella K, Dungan LS, Higgins SC, Kelly PJ, Costelloe L, Tubridy N, Mills KH, Fletcher JM. IL-27 mediates the response to IFN-beta therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun 2011,
45. McRae BL, Semnani RT, Hayes MP, van Seventer GA. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol 1998, 160:4298-4304.
46. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010, 16:406-412.
47. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31:331-341.
48. Kristjansdottir G, Sandling JK, Bonetti A, Roos IM, Milani L, Wang C, Gustafsdottir SM, Sigurdsson S, Lundmark A, Tienari PJ, Koivisto K, Elovaara I, Pirttila T, Reunanen M, Peltonen L, Saarela J, Hillert J, Olsson T, Landegren U, Alcina A, Fernandez O, Leyva L, Guerrero M, Lucas M, Izquierdo G, Matesanz F, Syvanen AC. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet 2008, 45:362-369.
49. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, Piccio L, Raychaudhuri S, Tran D, Aubin C, Briskin R, Romano S, Baranzini SE, McCauley JL, Pericak-Vance MA, Haines JL, Gibson RA, Naeglin Y, Uitdehaag B, Matthews PM, Kappos L, Polman C, McArdle WL, Strachan DP, Evans D, Cross AH, Daly MJ, Compston A, Sawcer SJ, Weiner HL, Hauser SL, Hafler DA, Oksenberg JR. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009, 41:776-782.
50. Fu Q, Zhao J, Qian X, Wong JL, Kaufman KM, Yu CY, Mok MY, Harley JB, Guthridge JM, Song YW, Cho SK, Bae SC, Grossman JM, Hahn BH, Arnett FC, Shen N, Tsao BP. Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum 2011, 63:749-754.